These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23665979)

  • 81. Intravitreal aflibercept for submacular hemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Kim JH; Kim CG; Lee DW; Yoo SJ; Lew YJ; Cho HJ; Kim JY; Lee SH; Kim JW
    Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):107-116. PubMed ID: 31741044
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Relation between changes in foveal choroidal thickness and 1-year results of ranibizumab therapy for polypoidal choroidal vasculopathy.
    Hikichi T; Kitamei H; Shioya S; Higuchi M; Matsushita T; Kosaka S; Matsushita R; Takami K; Ohtsuka H
    Br J Ophthalmol; 2014 Sep; 98(9):1201-4. PubMed ID: 24723615
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Two-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.
    Yamashita A; Shiraga F; Shiragami C; Shirakata Y; Fujiwara A
    Am J Ophthalmol; 2013 Jan; 155(1):96-102.e1. PubMed ID: 22995028
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy.
    Cho HJ; Baek JS; Lee DW; Cho SW; Kim CG; Kim JW
    Retina; 2013; 33(10):2126-32. PubMed ID: 23609123
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Prognostic factors of 2-year outcomes of ranibizumab therapy for polypoidal choroidal vasculopathy.
    Hikichi T; Kitamei H; Shioya S
    Br J Ophthalmol; 2015 Jun; 99(6):817-22. PubMed ID: 25480464
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Submacular hemorrhage and grape-like polyp clusters: factors associated with reactivation of the lesion in polypoidal choroidal vasculopathy.
    Kim JH; Chang YS; Kim JW; Kim CG; Lee DW
    Eye (Lond); 2017 Dec; 31(12):1678-1684. PubMed ID: 28707675
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.
    Yamazaki T; Koizumi H; Yamagishi T; Kinoshita S
    Ophthalmology; 2012 Aug; 119(8):1621-7. PubMed ID: 22551738
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Individualized ranibizumab therapy strategies in year 3 after as-needed treatment for polypoidal choroidal vasculopathy.
    Hikichi T
    BMC Ophthalmol; 2015 Apr; 15():37. PubMed ID: 25881324
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Photodynamic therapy, ranibizumab, and ranibizumab with photodynamic therapy for the treatment of polypoidal choroidal vasculopathy.
    Rouvas AA; Papakostas TD; Ntouraki A; Douvali M; Vergados I; Ladas ID
    Retina; 2011 Mar; 31(3):464-74. PubMed ID: 20948458
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Three-year visual outcomes of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy.
    Sakai T; Okano K; Kohno H; Tsuneoka H
    Acta Ophthalmol; 2016 Dec; 94(8):e765-e771. PubMed ID: 27237048
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Correlation of indocyanine green angiography and optical coherence tomography findings after intravitreal ranibizumab for polypoidal choroidal vasculopathy.
    Ueno C; Gomi F; Sawa M; Nishida K
    Retina; 2012; 32(10):2006-13. PubMed ID: 22772392
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy with polyps resembling grape clusters.
    Lee JH; Lee WK
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):645-51. PubMed ID: 26138657
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Five-year real-world outcomes of anti-vascular endothelial growth factor monotherapy versus combination therapy for polypoidal choroidal vasculopathy in a Chinese population: a retrospective study.
    Yang J; Yuan M; Wang E; Xia S; Chen Y
    BMC Ophthalmol; 2019 Nov; 19(1):237. PubMed ID: 31752769
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Distinct Responsiveness to Intravitreal Ranibizumab Therapy in Polypoidal Choroidal Vasculopathy With Single or Multiple Polyps.
    Suzuki M; Nagai N; Shinoda H; Uchida A; Kurihara T; Tomita Y; Kamoshita M; Iyama C; Tsubota K; Ozawa Y
    Am J Ophthalmol; 2016 Jun; 166():52-59. PubMed ID: 27017997
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Intravitreal ranibizumab therapy versus photodynamic therapy for idiopathic choroidal neovascularization: a comparative study on visual acuity, retinal and choroidal thickness.
    Shi X; Wei W; Zhang C
    Chin Med J (Engl); 2014; 127(12):2279-85. PubMed ID: 24931242
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Long-term prognosis of polypoidal choroidal vasculopathy with a 5-year remission after an initial combination therapy.
    Kikushima W; Sakurada Y; Yoneyama S; Sugiyama A; Matsubara M; Fukuda Y; Kashiwagi K
    Photodiagnosis Photodyn Ther; 2021 Sep; 35():102453. PubMed ID: 34303031
    [TBL] [Abstract][Full Text] [Related]  

  • 97. THE INCIDENCE, CHARACTERISTICS, MANAGEMENT, PROGNOSIS, AND CLASSIFICATION OF BREAKTHROUGH VITREOUS HEMORRHAGE SECONDARY TO POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Zhao XY; Luo MY; Meng LH; Zhang WF; Li B; Wang EQ; Liu SZ; Yu WH; Chen YX
    Retina; 2021 Aug; 41(8):1675-1685. PubMed ID: 33395221
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab.
    Sonoda S; Sakamoto T; Otsuka H; Yoshinaga N; Yamashita T; Ki-I Y; Okubo A; Yamashita T; Arimura N
    BMC Ophthalmol; 2013 Aug; 13():43. PubMed ID: 23962072
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response.
    Hatz K; Prünte C
    Br J Ophthalmol; 2014 Feb; 98(2):188-94. PubMed ID: 24246375
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Structural and Vascular Changes of the Choroid in Polypoidal Choroidal Vasculopathy after Intravitreal Anti-VEGF Therapy.
    Montorio D; Giordano M; Concilio M; Cennamo G
    Ophthalmologica; 2022; 245(2):173-178. PubMed ID: 34844252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.